50359
Voglibose
≥97.0% (TLC)
동의어(들):
3,4-Dideoxy-4-{[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-D-epi-inositol, N-(1,3-Dihydroxyprop-2-yl)valiolamine
로그인조직 및 계약 가격 보기
모든 사진(1)
크기 선택
보기 변경
10 MG
₩402,651
About This Item
실험식(Hill 표기법):
C10H21NO7
CAS Number:
Molecular Weight:
267.28
MDL number:
UNSPSC 코드:
12352201
PubChem Substance ID:
NACRES:
NA.25
추천 제품
생물학적 소스
synthetic
분석
≥97.0% (TLC)
양식
powder
색상
white
저장 온도
−20°C
SMILES string
OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O
InChI
1S/C10H21NO7/c12-2-5(3-13)11-6-1-10(18,4-14)9(17)8(16)7(6)15/h5-9,11-18H,1-4H2/t6-,7-,8+,9-,10-/m0/s1
InChI key
FZNCGRZWXLXZSZ-CIQUZCHMSA-N
유전자 정보
human ... GAA(2548) , MGAM(8972) , MGAM2(93432) , SI(6476)
애플리케이션
Voglibose is an α-glucosidase inhibitor, similar to acarbose and miglitol, used for lowering post-prandial hyperglycemia (PPHG) in people with diabetes mellitus. Voglibose is used to study it benefits as a protectant against ischemia-reperfusion injury through glucagon-like peptide 1 receptors and the phosphoinositide 3-kinase-Akt-endothelial nitric oxide synthase pathway.
포장
Bottomless glass bottle. Contents are inside inserted fused cone.
기타 정보
To gain a comprehensive understanding of our extensive range of Monosaccharides for your research, we encourage you to visit our Carbohydrates Category page.
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point (°F)
Not applicable
Flash Point (°C)
Not applicable
개인 보호 장비
Eyeshields, Gloves, type N95 (US)
이미 열람한 고객
Xiaolong Chen et al.
Current medicinal chemistry, 13(1), 109-116 (2006-02-07)
The number of people with diabetes is expected to rise from the current estimated 150 million to 220 million in 2010 and 300 million in 2025, and 90% is Type 2 diabetes or non-insulin dependent diabetes mellitus (NIDDM). Voglibose, one
Y Iwamoto et al.
Diabetes, obesity & metabolism, 12(7), 613-622 (2010-07-02)
To compare the efficacy and safety of sitagliptin (a dipeptidyl peptidase-4 inhibitor) and voglibose (an alpha-glucosidase inhibitor) monotherapy in Japanese patients with type 2 diabetes who have inadequate glycaemic control (HbA1c > or =6.5% and <10.0%) on diet and exercise.
Devasier Bennet et al.
International journal of nanomedicine, 7, 3399-3419 (2012-08-14)
Antioxidant (quercetin) and hypoglycemic (voglibose) drug-loaded poly-D,L-lactideco-glycolide nanoparticles were successfully synthesized using the solvent evaporation method. The dual drug-loaded nanoparticles were incorporated into a scaffold film using a solvent casting method, creating a controlled transdermal drug-delivery system. Key features of
Yutaka Seino et al.
Current medical research and opinion, 27 Suppl 3, 21-29 (2011-12-14)
To compare the efficacy and safety of alogliptin and placebo as add-on therapy in Japanese patients with type 2 diabetes who experienced inadequate glycemic control on voglibose plus diet/exercise therapy. During an 8 week screening phase, patients aged ≥ 20
R Kawamori et al.
Diabetes, obesity & metabolism, 14(4), 348-357 (2011-12-08)
To evaluate the efficacy and safety of linagliptin 5 and 10 mg vs. placebo and voglibose in Japanese patients with type 2 diabetes mellitus (T2DM). This study enrolled patients with inadequately controlled T2DM who were previously treated with one or
활성 필터
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.
